Matinas BioPharma's total assets for Q3 2025 were $9.70M, a decrease of -15.13% from the previous quarter. MTNB total liabilities were $3.23M for the fiscal quarter, a -13.71% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.